Company Overview
Snapshot
Founded in September 2010 by Daniel Levner and Yossi Pollak, Sight Diagnostics operates with 51–200 employees. The company has raised $123.8 million across 5 funding rounds from 13 investors, with OurCrowd as a notable lead investor. In October 2022, Sight Diagnostics deployed its OLO hematology analyzer in Trinidad and Tobago, marking its first Caribbean installation and expanding its global reach for rapid blood count testing.
Business overview
Sight Diagnostics develops advanced blood diagnostics platforms leveraging computer vision and machine learning. Its core products include the Parasight platform for malaria diagnosis and the OLO analyzer, a point-of-care complete blood count (CBC) platform. The company's technology provides lab-grade results in minutes, serving doctors' offices, emergency medical centers, and laboratories. Sight Diagnostics operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices, aiming to enhance diagnostic approaches for various diseases.
Strategic signal
In April 2026, Sight Diagnostics' board initiated further employee reductions, indicating ongoing struggles to maintain operations. This follows significant restructuring and layoffs in May and September 2024, which saw the company's workforce shrink considerably. This trend signals a challenging period for the company, suggesting a need for strategic re-evaluation or a significant pivot to ensure long-term viability.
Log in to access full profile ›Company Intelligence Q&A
- What is the current operational status of Sight Diagnostics?
- In April 2026, Sight Diagnostics' board moved to cut final employees as the company struggles to continue operations, following previous significant workforce reductions in 2024.
- What significant organizational changes occurred at Sight Diagnostics in September 2024?
- In September 2024, Sight Diagnostics underwent extensive layoffs, reducing its workforce from 250 to 70 employees, with plans for further reductions to 40. This restructuring followed the departure of its founder and a strategic realization that blood counting was a solved problem, prompting the company to attempt reinvention.
- What was a key product deployment milestone for Sight Diagnostics in the Caribbean?
- In October 2022, Sight Diagnostics deployed its first portable hematology analytical instrument, the OLO, in the Caribbean, specifically in Trinidad and Tobago. This device provides near-immediate Complete Blood Count (CBC) results for critical care, oncology, and pediatric patients.
- When did Sight Diagnostics receive Health Canada approval for its OLO analyzer?
- In January 2022, Sight Diagnostics received Health Canada approval for its Sight OLO analyzers for point-of-care settings. This allowed the company to offer 5-part differential Complete Blood Count (CBC) testing in emergency departments, hospitals, and decentralized settings across Canada.
- What was a key partnership for Sight Diagnostics in March 2021?
- In March 2021, Sight Diagnostics partnered with Oxford University to deploy its Sight OLO solution at the John Radcliffe Hospital. This collaboration enabled quick Full Blood Count (FBC) testing as part of a rapid AI triage system for Covid-19, reducing FBC result times to 30 minutes.